Search

Your search keyword '"Sokal, Etienne"' showing total 1,927 results

Search Constraints

Start Over You searched for: Author "Sokal, Etienne" Remove constraint Author: "Sokal, Etienne"
1,927 results on '"Sokal, Etienne"'

Search Results

1. Type of calcineurin inhibitor and long-term outcomes following liver transplantation in patients with primary biliary cholangitis – an ELTR study

2. Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

3. Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial

5. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

7. Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis

8. Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection

9. Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency

11. THU-092 Enrolling patients in ACLF trials-the need to increase ACLF awareness (DHELIVER trial)

12. Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders—A successful strategy for clinical research of rare diseases

13. Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler

14. Failure to Rescue Pediatric Recipients of Living Donor Liver Transplantation: A Single‐Center Study of Technical Complications in 500 Primary Grafts.

15. Favorable Outcome after Liver Transplantation in an Infant with Liver Failure Due to Deoxyguanosine Kinase Deficiency.

17. Outcomes of surgical management of familial intrahepatic cholestasis 1 and bile salt export protein deficiencies.

18. Type of calcineurin inhibitor and long-term outcomes following liver transplantation in patients with Primary Biliary Cholangitis- an ELTR study

19. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study

20. A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation

22. Immune regulation and therapeutic application of T regulatory cells in liver diseases

25. Genotype correlates with the natural history of severe bile salt export pump deficiency

29. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

33. Sofosbuvir–velpatasvir in children 3–17 years old with hepatitis C virus infection

34. ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource‐limited settings.

35. P1 Analysis of long-term treatment effects of odevixibat on clinical outcomes in children with progressive familial intrahepatic cholestasis in odevixibat clinical studies vs external controls from the NAPPED database

40. Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity

41. Biological tests carried out on serum/plasma samples from donors of human body material for transplantation: Belgian experience and practical recommendations

44. Analysis of safety in maralixibat-treated participants with progressive familial intrahepatic cholestasis: data from MARCH-PFIC

45. Efficacy and safety outcomes with odevixibat treatment: Pooled data from the phase 3 ASSERT and ASSERT-EXT studies in patients with Alagille syndrome

46. Safety, tolerability, and preliminary efficacy of ascending doses of Human Allogeneic Liver-derived Progenitor Cells (HepaStem®) in patients with cirrhotic and pre-cirrhotic non-alcoholic steatohepatitis (NASH)

47. Analysis of long-term treatment effects of odevixibat on clinical outcomes in children with progressive familial intrahepatic cholestasis in odevixibat clinical studies vs external controls from the NAPPED database

48. Serum bile acids are associated with native liver survival in patients with Alagille syndrome: results from the GALA study group

49. Long-term maintenance of response and improved liver health with maralixibat in patients with progressive familial intrahepatic cholestasis (PFIC): data from the MARCH-ON study

50. ACLF course profiles over screening period in the phase IIb DHELIVER study

Catalog

Books, media, physical & digital resources